IQVIA Holdings Inc. Supplies Critical Real‑World Evidence for Neurocrine Biosciences’ Tardive Dyskinesia Study
IQVIA Holdings Inc. remains a pivotal resource for the pharmaceutical industry, providing high‑resolution, longitudinal claims data that enable rigorous assessment of real‑world clinical outcomes. In a recent presentation by Neurocrine Biosciences, the company’s extensive claims database was leveraged to conduct a head‑to‑head comparison of two FDA‑approved agents used to treat tardive dyskinesia (TD) – the VMAT2 inhibitor INGREZZA (valbenazine) and the antipsychotic AUSTEDO XR (aripiprazole).
Study Design and Population
The observational analysis incorporated data from nearly 3,000 patients across the United States who initiated therapy with either INGREZZA or AUSTEDO XR between 2022 and 2024. Patients were followed for a 6‑month period post‑initiation, allowing the investigators to evaluate treatment persistence, switching behavior, and time to discontinuation. IQVIA’s claims database provided comprehensive pharmacy fill information, inpatient and outpatient encounters, and demographic variables, ensuring a robust capture of real‑world medication adherence patterns.
Clinical Findings
- Higher Treatment Persistence with INGREZZA
- 68 % of patients prescribed INGREZZA remained on therapy at 6 months, compared with 53 % of AUSTEDO XR users.
- Kaplan–Meier analysis demonstrated a statistically significant difference in survival curves (log‑rank p < 0.01).
- Reduced Switching Rates
- Only 12 % of INGREZZA patients switched to an alternative TD therapy within 6 months, versus 27 % of AUSTEDO XR patients.
- Extended Median Time to Discontinuation
- Median time to discontinuation was 4.7 months for INGREZZA versus 3.2 months for AUSTEDO XR (Hazard Ratio = 0.71, 95 % CI 0.60–0.84).
These metrics suggest that sustained exposure to INGREZZA may reduce relapse risk and alleviate patient burden by maintaining symptom control over a longer period.
Pharmacologic Rationale
Tardive dyskinesia arises from chronic dopamine receptor blockade, leading to dopaminergic supersensitivity and involuntary movements. INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor that decreases presynaptic dopamine packaging, thereby attenuating dopamine release without direct receptor antagonism. This mechanism preserves dopaminergic tone while mitigating the hyperkinetic activity characteristic of TD.
Conversely, AUSTEDO XR is a partial agonist at dopamine D2/D3 receptors and serotonin 5‑HT1A receptors. While it modulates dopaminergic signaling, its efficacy for TD is primarily extrapolated from its antipsychotic activity rather than a dedicated anti‑dyskinetic mechanism. The differential pharmacodynamics likely contribute to the observed disparities in treatment persistence.
Regulatory and Market Context
INGREZZA received FDA approval in 2018 for the treatment of TD, supported by randomized controlled trials demonstrating significant reductions in the Abnormal Involuntary Movement Scale (AIMS). Post‑marketing surveillance and real‑world studies, such as the IQVIA‑based analysis, continue to validate its efficacy and safety profile in routine clinical practice.
AUSTEDO XR (aripiprazole) is indicated for schizophrenia, bipolar disorder, and adjunctive treatment of major depressive disorder. Its off‑label use for TD has been explored in smaller clinical studies; however, the evidence base remains less robust compared with INGREZZA.
The comparative effectiveness data supplied by IQVIA provide payers, clinicians, and manufacturers with actionable insights that can inform formulary decisions, reimbursement strategies, and clinical practice guidelines.
IQVIA’s Role and Future Opportunities
IQVIA’s ability to translate vast volumes of pharmacy and medical claims into granular, actionable analytics underscores its strategic value. By enabling comparative effectiveness studies that span diverse therapeutic areas, IQVIA facilitates evidence‑based decision making for all stakeholders—clinicians seeking optimal patient outcomes, payers aiming for cost‑effective coverage, and drug developers evaluating market performance.
As the industry increasingly adopts real‑world evidence (RWE) to complement randomized controlled trials, IQVIA’s data infrastructure positions it as a critical partner for pharmaceutical innovation. The Neurocrine study exemplifies how real‑world persistence metrics can illuminate the clinical and economic advantages of a medication, ultimately shaping therapeutic strategies and regulatory submissions.
In summary, the IQVIA‑driven analysis offers a scientifically rigorous, real‑world perspective on the comparative effectiveness of INGREZZA versus AUSTEDO XR in treating tardive dyskinesia. While the findings are encouraging for INGREZZA’s sustained use, further prospective studies and long‑term outcome data will continue to refine our understanding of these therapies in diverse patient populations.
